Bone resorption inhibitors

Bisphosphonates are inhibitors of bone resorption. They increase bone mineral density by altering osteoclast activation and function. Alendronate and

by S Zhou 2024 Cited by 48Currently, the main therapeutic drugs for osteoporosis are bone resorption inhibitors [[115], [116], [117]]. These drugs inhibit bone resorption

by HN Rosen Cited by 12inhibition of bone resorption. In normal bone remodeling, bone resorption and formation are coupled. Changes in resorption drive formation

Bone resorption inhibitors are mainly used to prevent fractures in patients with osteoporosis. By blocking the action of osteoclasts, bone resorption is

by S Zhou 2024 Cited by 48Currently, the main therapeutic drugs for osteoporosis are bone resorption inhibitors [[115], [116], [117]]. These drugs inhibit bone resorption

All bisphosphonates inhibit bone resorption by attaching to hydroxyapatite binding sites on the bone, particularly in areas with active resorption. As osteoclasts resorb bone, the bisphosphonate embedded in the bone is released and impairs the osteoclast s ability to continue bone resorption.

Bone resorption inhibitors are drugs that inhibit mineralization or resorption of the bone by blocking the action of osteoclasts. They are used to treat postmenopausal and glucocorticoid induced osteoporosis, Paget's disease of the bone and malignant hypercalcemia .

Another class of bone resorption inhibitors includes bisphosphonates, such as alendronate and zoledronic acid. These drugs bind to bone minerals

bone formation. Background: The aim of this study was to evaluate the effects of bone resorption inhibitors, doxycycline (DOX) and erythromycin (EM), on